N/A
Completed N=53
Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?
Chronic Renal Failure
Source: ClinicalTrials.gov NCT02420119 ↗
Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcomePrimary: Decrease in Serum Levels of Phosphorus in Patients After Treatment With Intravenous Iron. — 3.47 mg/dL
Summary
Intravenous iron therapy is common and effective, with few side effects. Two formulations are used, venofer or iron sucrose and ferrlecit, or ferric gluconate.
The association between intravenous iron use and decrease in serum phosphorus and vitamin D levels, with increased fractional excretion of phosphorus, has been observed with older iron preparations, such as saccharated ferric oxide. However, hypophosphatemia and osteomalacia have been reported with iron carboxymaltose, a newer iron formulation. There is no information in the literature about phosphorus and vitamin D levels after treatment with venofer or ferrlecit. We intend to check phosphorus and vitamin D serum levels in our patients prior to and after treatment with these iron formulations.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Decrease in Serum Levels of Phosphorus in Patients After Treatment With Intravenous Iron. |
3.47 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 and over
- Have an indication for intravenous iron treatment
- Estimated Creatinine clearance at least 30ml/min (patients with lower Estimated Creatinine clearance may not be able to excrete phosphorus)
- Have signed informed consent.
Exclusion Criteria
- Pregnancy
- Estimated creatinine clearance below 30 ml/min.
Data sourced from ClinicalTrials.gov (NCT02420119). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.